Evaluation of Efficacy and Safety of Nab-Paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer
JAMA Oncol
.
2021 Apr 1;7(4):633-634.
doi: 10.1001/jamaoncol.2020.8005.
Authors
Satoshi Funada
1
2
,
Takashi Yoshioka
3
4
,
Yan Luo
2
Affiliations
1
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto City, Kyoto, Japan.
2
Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine and School of Public Health, Kyoto, Japan.
3
Center for Innovative Research for Communities and Clinical Excellence (CiRC 2 LE), Fukushima Medical University, Fukushima City, Fukushima, Japan.
4
Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine and School of Public Health, Kyoto, Japan.
PMID:
33570545
DOI:
10.1001/jamaoncol.2020.8005
No abstract available
Publication types
Letter
Comment
MeSH terms
Albumins / adverse effects
Canada
Carcinoma, Transitional Cell*
Humans
Paclitaxel / adverse effects
Platinum*
Substances
130-nm albumin-bound paclitaxel
Platinum
Paclitaxel
Albumins